| 词条 | Mebeverine |
| 释义 |
| Watchedfields = changed | verifiedrevid = 443346749 | IUPAC_name = (RS)-4-(Ethyl[1-(4-methoxyphenyl)propan-2-yl]amino)butyl 3,4-dimethoxybenzoate | image = Mebeverine.svg | width = 300 | image2 = Mebeverine2.png | chirality = Racemic mixture | tradename = | Drugs.com = {{drugs.com|international|mebeverine}} | pregnancy_AU = | pregnancy_US = | legal_AU = | legal_UK = P | legal_US = Not approved | legal_status = Rx-only | routes_of_administration = By mouth | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 2753-45-9 | ATC_prefix = A03 | ATC_suffix = AA04 | PubChem = 4031 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 3891 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 7F80CC3NNV | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D04868 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 282121 | C=25 | H=35 | N=1 | O=5 | molecular_weight = 429.6 g/mol | smiles = O=C(OCCCCN(C(C)Cc1ccc(OC)cc1)CC)c2cc(OC)c(OC)cc2 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = VYVKHNNGDFVQGA-UHFFFAOYSA-N }}Mebeverine is a drug used to alleviate some of the symptoms of irritable bowel syndrome. It works by relaxing the muscles in and around the gut.[1] Medical useMebeverine is used to alleviate some of the symptoms of irritable bowel syndrome (IBS) and related conditions; specifically stomach pain and cramps, persistent diarrhea, and flatulence.[2] Data from controlled clinical trials have not found a difference from placebo in the alleviating stomach pain in people with IBS.[3][4] It has not been tested in pregnant women nor in pregnant animals so pregnant women should not take it; it is expressed at low levels in breast milk, while no adverse effects have been reported in infants, breastfeeding women should not take this drug.[1] Adverse effectsAdverse effects include hypersensitivity reactions and allergic reactions, immune system disorders, skin disorders including hives, edema and widespread rashes.[2] Additionally, the following adverse effects have been reported: heartburn, indigestion, tiredness, diarrhea, constipation, loss of appetite, general malaise, dizziness, insomnia, headache, and decreased pulse rate.[1] It does not have systemic anticholinergic side effects.[2] Mebeverine can, on highly rare occasions, cause drug-induced acute angle closure glaucoma.[5] Mechanism of actionMebeverine is an anticholinergic but its mechanism of action is not known; it appears to work directly on smooth muscle within the gastrointestinal tract and may have an anesthetic effect, may affect calcium channels, and may affect muscarinic receptors.[2] It is metabolized mostly by esterases, and almost completely. The metabolites are excreted in urine.[2] Mebeverine exists in two enantiomeric forms. The commercially available product is a racemic mixture of them. A study in rats indicates that the two have different pharmacokinetic profiles.[6] HistoryIt is a second generation papaverine analog, and was first synthesized around the same time as verapamil.[7] It was first registered in 1965.[8] AvailabilityMebeverine is a generic drug and is available internationally under many brand names.[9] References1. ^1 2 {{cite web|title=Colofac data sheet|url=http://www.medsafe.govt.nz/profs/datasheet/c/colofactab.pdf|publisher=New Zealand Medicines and Medical Devices Safety Authority|accessdate=21 July 2017|date=14 June 2017}} {{Drugs for functional gastrointestinal disorders}}{{Muscarinic acetylcholine receptor modulators}}2. ^1 2 3 4 {{cite web|title=Colofac Tablets 135mg - Summary of Product Characteristics (SPC)|url=https://www.medicines.org.uk/emc/medicine/2067|publisher=UK Electronic Medicines Compendium|accessdate=21 July 2017|language=en|date=26 August 2016}} 3. ^{{cite journal|last1=Annaházi|first1=A|last2=Róka|first2=R|last3=Rosztóczy|first3=A|last4=Wittmann|first4=T|title=Role of antispasmodics in the treatment of irritable bowel syndrome|journal=World Journal of Gastroenterology|date=28 May 2014|volume=20|issue=20|pages=6031–43|doi=10.3748/wjg.v20.i20.6031|pmid=24876726|pmc=4033443}} 4. ^{{cite journal|last1=Darvish-Damavandi|first1=M|last2=Nikfar|first2=S|last3=Abdollahi|first3=M|title=A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome|journal=World Journal of Gastroenterology|date=7 February 2010|volume=16|issue=5|pages=547–53|pmid=20128021|pmc=2816265|doi=10.3748/wjg.v16.i5.547}} 5. ^{{cite journal |last1=Lachkar |first1=Y |last2=Bouassida |first2=W |title=Drug-induced acute angle closure glaucoma |journal=Current Opinion in Ophthalmology |date=March 2007 |volume=18 |issue=2 |pages=129–33 |doi=10.1097/ICU.0b013e32808738d5 |pmid=17301614}} 6. ^{{cite journal |title= Fiber‐Based Liquid‐Phase Micro‐Extraction of Mebeverine Enantiomers Followed by Chiral High‐Performance Liquid Chromatography Analysis and Its Application to Pharmacokinetics Study in Rat Plasma |journal= Chirality |first1= Mehdi |last1= Hatami |first2= Khalil |last2= Farhadi |first3= Amir |last3= Tukmechi |doi= 10.1002/chir.22057 |pmid= 22700279 |volume= 24 |issue= 8 |date= August 2012 |pages= 634–639 }} 7. ^{{cite book|last1=Sneader|first1=Walter|title=Drug Discovery: A History|date=2005|publisher=John Wiley & Sons|isbn=9780471899792|page=132|url=https://books.google.com/books?id=Cb6BOkj9fK4C&pg=PA132|language=en}} 8. ^Mebeverine page at druginfosys Page accessed Feb 1, 2015 9. ^[https://www.drugs.com/international/mebeverine.html International page at drugs.com for Mebeverine] Page accessed Feb 1, 2015 5 : Amines|Benzoates|Motility stimulants|Muscarinic antagonists|Phenol ethers |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。